Petronella O. Witteveen

9.2k total citations · 1 hit paper
95 papers, 3.8k citations indexed

About

Petronella O. Witteveen is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Petronella O. Witteveen has authored 95 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 35 papers in Reproductive Medicine and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Petronella O. Witteveen's work include Ovarian cancer diagnosis and treatment (34 papers), Colorectal Cancer Treatments and Studies (13 papers) and Lung Cancer Treatments and Mutations (12 papers). Petronella O. Witteveen is often cited by papers focused on Ovarian cancer diagnosis and treatment (34 papers), Colorectal Cancer Treatments and Studies (13 papers) and Lung Cancer Treatments and Mutations (12 papers). Petronella O. Witteveen collaborates with scholars based in Netherlands, United States and Germany. Petronella O. Witteveen's co-authors include Ignace Vergote, Éric Pujade-Lauraine, Felix Hilpert, Aristotelis Bamias, Gunnar B. Kristensen, Roberto Sorio, Andrés Poveda, David T. Bollag, Isabelle Ray‐Coquard and Ana Oaknin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Petronella O. Witteveen

90 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

2014 1.1k citations Éric Pujade-Lauraine, Felix Hilpert et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Petronella O. Witteveen Netherlands	29	2.0k	1.5k	807	799	702	95	3.8k
Felix Hilpert Germany	29	1.6k 0.8×	2.5k 1.6×	762 0.9×	477 0.6×	1.0k 1.4×	172	3.9k
Roberto Sorio Italy	26	1.7k 0.8×	1.7k 1.1×	915 1.1×	560 0.7×	613 0.9×	129	3.6k
Anne Floquet France	30	1.3k 0.7×	1.2k 0.8×	442 0.5×	758 0.9×	665 0.9×	170	3.3k
Edgar Petru Austria	33	1.5k 0.7×	1.5k 1.0×	691 0.9×	898 1.1×	749 1.1×	222	3.9k
Bhavana Pothuri United States	30	1.2k 0.6×	1.1k 0.7×	1.1k 1.3×	363 0.5×	686 1.0×	203	3.4k
Neil S. Horowitz United States	42	1.2k 0.6×	2.0k 1.3×	986 1.2×	442 0.6×	1.1k 1.6×	214	4.9k
Vicky Makker United States	34	1.9k 0.9×	1.5k 1.0×	975 1.2×	953 1.2×	592 0.8×	180	4.6k
Kenneth D. Swenerton Canada	26	2.2k 1.1×	2.3k 1.5×	1.2k 1.5×	598 0.7×	574 0.8×	55	4.6k
W. Lichtenegger Germany	35	1.8k 0.9×	1.6k 1.0×	1.0k 1.3×	548 0.7×	983 1.4×	243	4.6k
Carolyn Krasner United States	26	1.0k 0.5×	1.2k 0.8×	627 0.8×	528 0.7×	463 0.7×	107	2.5k

Countries citing papers authored by Petronella O. Witteveen

Since Specialization

Citations

This map shows the geographic impact of Petronella O. Witteveen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petronella O. Witteveen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petronella O. Witteveen more than expected).

Fields of papers citing papers by Petronella O. Witteveen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Petronella O. Witteveen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petronella O. Witteveen. The network helps show where Petronella O. Witteveen may publish in the future.

Co-authorship network of co-authors of Petronella O. Witteveen

This figure shows the co-authorship network connecting the top 25 collaborators of Petronella O. Witteveen. A scholar is included among the top collaborators of Petronella O. Witteveen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petronella O. Witteveen. Petronella O. Witteveen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hami, Nizar, Hans W. Nijman, Jurgen M.J. Piek, et al.. (2025). The Prognostic Value of FOXL2 Mutant Circulating Tumor DNA in Adult Granulosa Cell Tumor Patients. Cancers. 17(11). 1894–1894.

Groeneweg, Jolijn W., et al.. (2022). Response to Systemic Therapies in Ovarian Adult Granulosa Cell Tumors: A Literature Review. Cancers. 14(12). 2998–2998. 20 indexed citations

Egberts, Toine C. G., et al.. (2022). The association between patient satisfaction with information and adherence to oral anticancer agents. Journal of Oncology Pharmacy Practice. 29(3). 637–645.

Janssen, Julie M., Kristel Van Calsteren, Thomas P. C. Dorlo, et al.. (2021). Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP). Clinical Pharmacokinetics. 60(6). 775–784. 18 indexed citations

Triest, Baukelien van, Jacobus van der Velden, Joanne A. de Hullu, et al.. (2021). Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study. Gynecologic Oncology. 163(1). 117–124. 15 indexed citations

Berg, M. van den, Annelies M. E. Bos, Marieke C.S. Boshuizen, et al.. (2021). Development and testing of a tailored online fertility preservation decision aid for female cancer patients. Cancer Medicine. 10(5). 1576–1588. 14 indexed citations

Bos, Frederiek van den, et al.. (2020). Validation of the G8 screening tool in older patients with cancer considered for surgical treatment. Journal of Geriatric Oncology. 12(5). 793–798. 28 indexed citations

Schram, Alison M., Alexander Drilon, Teresa Macarulla, et al.. (2020). A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). TPS3654–TPS3654. 17 indexed citations

Emmelot‐Vonk, Mariëlle H., et al.. (2019). Predictive value of each geriatric assessment domain for older patients with cancer: A systematic review. Journal of Geriatric Oncology. 10(6). 859–873. 47 indexed citations

10.

Lankheet, Nienke A. G., et al.. (2018). Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study. Supportive Care in Cancer. 26(8). 2641–2650. 2 indexed citations

11.

Infante, Jeffrey R., Philippe A. Cassier, John F. Gerecitano, et al.. (2016). A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clinical Cancer Research. 22(23). 5696–5705. 237 indexed citations

12.

Amant, Frédéric, Tineke Vandenbroucke, Magali Verheecke, et al.. (2016). Pediatric Outcome After Maternal Cancer Diagnosed During Pregnancy. Obstetrical & Gynecological Survey. 71(3). 144–146. 6 indexed citations

13.

Sorio, Roberto, C. Roemer-Bécuwe, Felix Hilpert, et al.. (2016). Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecologic Oncology. 144(1). 65–71. 22 indexed citations

14.

Münster, Pamela N., Rahul Aggarwal, David S. Hong, et al.. (2015). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 22(8). 1932–1939. 83 indexed citations

15.

Pujade-Lauraine, Éric, Felix Hilpert, B. Weber, et al.. (2014). Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. Journal of Clinical Oncology. 32(13). 1302–1308. 1117 indexed citations breakdown →

16.

Pujade-Lauraine, Éric, Felix Hilpert, B. Weber, et al.. (2014). Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer. Obstetrical & Gynecological Survey. 69(7). 402–404. 20 indexed citations

17.

Hoogstraat, Marlous, Mirjam S. de Pagter, Geert A. Cirkel, et al.. (2013). Genomic and transcriptomic plasticity in treatment-naïve ovarian cancer. Genome Research. 24(2). 200–211. 63 indexed citations

18.

Devriese, Lot A., Petronella O. Witteveen, Silvia Marchetti, et al.. (2012). Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemotherapy and Pharmacology. 70(6). 823–832. 37 indexed citations

19.

Sharma, Sunil, Emile E. Voest, Nicole Hagner, et al.. (2011). Effects of Renal Function on the Pharmacokinetics of Panobinostat in Patients with Advanced Cancer: A Phase I Study. Blood. 118(21). 5001–5001. 2 indexed citations

20.

Walraven, Maudy, Petronella O. Witteveen, Martijn P. Lolkema, et al.. (2010). Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis. 14(2). 135–141. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact